[1]张卉青,韦卓纯,林 绘,等.利用生物信息学方法分析青黛治疗溃疡性结肠炎的药理作用机制[J].医学信息,2024,37(06):7-13.[doi:10.3969/j.issn.1006-1959.2024.06.002]
　ZHANG Hui-qing,WEI Zhuo-chun,LIN Hui,et al.Pharmacological Mechanism of Qingdai in the Treatment of Ulcerative Colitis by Bioinformatics Methods[J].Journal of Medical Information,2024,37(06):7-13.[doi:10.3969/j.issn.1006-1959.2024.06.002]
点击复制

利用生物信息学方法分析青黛治疗溃疡性结肠炎的药理作用机制()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年06期
页码:
7-13
栏目:
生物信息学
出版日期:
2024-03-15

文章信息/Info

Title:
Pharmacological Mechanism of Qingdai in the Treatment of Ulcerative Colitis by Bioinformatics Methods
文章编号:
1006-1959（2024）06-0007-07
作者:
张卉青; 韦卓纯; 林 绘; 等
（1.东莞市滨海湾中心医院临床药学科，广东 东莞 523900；2.青岛市即墨区人民医院药剂科，山东 青岛 266200；3.上海市北蔡社区卫生院药剂科，上海 200000）
Author(s):
ZHANG Hui-qing; WEI Zhuo-chun; LIN Hui; et al.
(1.Department of Clinical Pharmacy,Dongguan Marina Bay Central Hospital,Dongguan 523900,Guangdong,China;2.Department of Pharmacy,Qingdao Jimo District People’s Hospital,Qingdao 266200,Shandong,China;3.Department of Pharmacy,Shanghai Beicai Community Health Center,Shanghai 200000,China)
关键词:
青黛; 溃疡性结肠炎; 炎性因子; 网络药理学; 靶点预测
Keywords:
Qingdai; Ulcerative colitis; Inflammatory factor; Network pharmacology; Target prediction
分类号:
R285.5
DOI:
10.3969/j.issn.1006-1959.2024.06.002
文献标志码:
A
摘要:
目的 通过网络药理学方法探索青黛治疗溃疡性结肠炎的药理作用机制。方法 通过中药系统药理学数据库与分析平台（TCMSP）数据库获得青黛的主要化学成分及其有效靶点，根据药物代谢动力学参数筛选有效活性成分和潜在作用靶点，通过GeneCards、OMIM、TTD、DRUGBANK数据库获取溃疡性结肠炎的潜在治疗靶点，通过制作韦恩图得到共同靶点；应用String数据库进行蛋白质相互作用分析，并构建PPI网络图挖掘潜在的蛋白质功能模块，并进行GO和KEGG富集分析；通过Cytoscape3.7.2软件构建“药物成分-靶点-通路”网络图，并进行数据分析。结果 共筛选到64个青黛成分靶点，溃疡性结肠炎相关靶点1599个，从而得到药物-疾病共靶点32个，富集于细胞因子受体（cytokine receptor binding）、DNA结合转录因子（DNA-binding transcription factor binding）、血红素结合（heme binding）等生物学功能，以及脂质和动脉粥样硬化（lipid and atherosclerosis）、乙型肝炎（hepatitis B）、EB病毒感染（epstein-bar virus infection）等疾病相关信号通路。结论 青黛治疗溃疡性结肠炎的主要活性成分为靛玉红，主要通过调节RELA、TNF、IKBKB、CASP3、MAPK14、CASP8等靶点，抑制细胞炎症反应，改善肠道上皮细胞功能，从而达到治疗溃疡性结肠炎的目的。
Abstract:
Objective To explore the pharmacological mechanism of Qingdai in the treatment of ulcerative colitis by network pharmacology.Methods The main chemical components and effective targets of Qingdai were obtained through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database. The effective active components and potential targets were screened according to the pharmacokinetic parameters. The potential therapeutic targets of ulcerative colitis were obtained through GeneCards, OMIM, TTD and DRUGBANK databases, and the co-targets were obtained by making Venn diagram. String database was used for protein interaction analysis, PPI network diagram was constructed to mine potential protein function modules, and GO and KEGG enrichment analysis were performed. The "drug component-target-pathway" network diagram was constructed by Cytoscape 3.7.2 software and data analysis was performed.Results A total of 64 Qingdai component targets and 1599 ulcerative colitis-related targets were screened, and 32 drug-disease co-targets were obtained, which were enriched in biological functions such as cytokine receptor binding, DNA-binding transcription factor binding, and heme binding, as well as lipid and atherosclerosis (lipid and atherosclerosis), hepatitis B (hepatitis B), EB virus infection (epstein-bar virus infection) and other disease-related signaling pathways.Conclusion Indirubin is the main active ingredient of Qingdai in the treatment of ulcerative colitis, mainly by regulating RELA, TNF, IKBKB, CASP3, MAPK14, CASP8 and other targets, inhibiting cellular inflammatory response, improving intestinal epithelial cell function, so as to achieve the purpose of treating ulcerative colitis.

参考文献/References:

[1]Teigen LM,Geng Z,Sadowsky MJ,et al.Dietary factors in sulfur metabolism and pathogenesis of ulcerativecolitis[J].Nutrients,2019,11(4):931.[2]Georgiou AN,Ntritsos G,Papadimitriou N,et al.Cigarette smoking,coffee consumption,alcohol intake,andrisk of crohn’s disease and ulcerative colitis: A mendelianrandomization study[J].Inflamm Bowel Dis,2021,27(2):162-168.[3]Moazzami B,Moazzami K,Rezaei N.Early onset inflammatory bowel disease: manifestations, genetics and diagnosis[J].Turk J Pediatr,2019,61(5):637-647.[4]Wu Y,Tang L,Wang B,et al.The role of autophagyin maintaining intestinal mucosal barrier[J].J Cell Physiol,2019,234(11):19406-19419.[5]Lei Y,Chen Y,Lin Z,et al.Comprehensive analysis of key biomarkers,immune infiltration and potential therapeutic agents for ulcerative colitis[J].Life Sci,2020,260:118437.[6]Xuan-Qing CHEN,Xiang-Yu LV,Shi-Jia LIU.Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway[J].J Ethnopharmacol,2021,265:113357.[7]Yan ZX,Liu YM,Ma T,et al.Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: A meta-analysis of randomized controlled trials[J].Complement Ther Clin Pract,2021,42:101278.[8]Lin YK,Chang SH,Yang CY,et al.Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial[J].J Ethnopharmacol,2020,250:112477.[9]马文强,杨坤,田昕,等.青黛对溃疡性结肠炎小鼠的治疗作用及其治疗机制研究[J].解剖科学进展,2019,25(2):146-149．[10]Lou Y,Ma Y,Jin J,et al.Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia[J].Front Oncol,2021,10:597601.[11]中华中医药学会脾胃病分会,沈洪,唐志鹏,等.消化系统常见病溃疡性结肠炎中医诊疗指南(基层医生版)[J].中华中医药杂志,2019,34(9):4155-4160.[12]Ng SC,Shi HY,Hamidi N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J].Lancet,2017,390(10114):2769-2778.[13]Zeng ZR,Zhu ZH,Yang YY,et al.Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong province,China: A prospective population-based study[J].J Gastroenterol Hepatol,2013,28(7):1148-1153.[14]Yang H,Li YM,Wu W,et al.The incidence of inflammatory bowel disease in Northern China:A prospective population-based study[J].PLoS One,2014,9(7):e101296[15]Semiz A,Ozgun Acar O,Cetin H,et al.Suppression of Inflammatory Cytokines Expression with Bitter Melon (Momordica Charantia) in TNBS-instigated Ulcerative Colitis[J].J Transl Int Med,2020,8(3):177-187.[16]Khare V,Tabassum S,Chatterjee U,et al.RNA helicase p68 deploys β-catenin in regulating RelA/p65 gene expression: implications in colon cancer[J].J Exp Clin Cancer Res,2019,38(1):330.[17]Papoutsopoulou S,Morris L,Bayliff A,et al.Effects of Human RelA Transgene on Murine Macrophage Inflammatory Responses[J].Biomedicines,2022,10(4):757.[18]Smith EL,Somma D,Kerrigan D,et al.The regulation of sequence specific NF-κB DNA binding and transcription by IKKβ phosphorylation of NF-κB p50 at serine 80[J].Nucleic Acids Res,2019,47(21):11151-11163.[19]殷娟,唐西怀,贾晶晶.溃疡性结肠炎患者的肠道菌群分布与血清TNF-α,IL-6水平的相关性[J].检验医学与临床,2019, 16(23):3421-3423,3426.[20]杨甜,吴八路,江宏强,等.MAPK14与胃癌放疗抵抗机制实验研究[J].中华肿瘤防治杂志,2019,26(21):1599-1605.[21]杨强,钦丹萍,杨新艳,等.Fas/FasL,p38MAPK通路在溃疡性结肠炎大鼠中的表达及雷公藤多苷的作用[J].中国药理学通报,2019,35(2):218-223.[22]贾育新,毕殿勇,段永强,等.参苓白术散对脾虚湿困型溃疡性结肠炎大鼠结肠p38MAPK及TNF-α,IL-4的干预作用[J].中医药学报,2018,46(5):11-17.[23]李亚兰,刘佳静,马沛广,等.葛根芩连汤调控MMP-9/p38 MARK途径修复溃疡性结肠炎小鼠肠黏膜上皮屏障功能[J].中国实验方剂学杂志,2021,27(4):8-15.[24]马文强,杨坤,田昕,等.青黛对溃疡性结肠炎小鼠的治疗作用及其治疗机制研究[J].解剖科学进展,2019,25(2):146-149.[25]Xiao HT,Peng J,Hu DD,et al.Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice[J].Chin Med,2015,10:29.[26]Yang L,Li X,Huang W,et al.Pharmacological properties of indirubin and its derivatives[J].Biomed Pharmacother,2022,151:113112.[27]Li Z,Wang H,Wei J,et al.Indirubin exerts anticancer effects on human glioma cells by inducing apoptosis and autophagy[J].AMB Express,2020,10(1):171.[28]刘丽娟,王允亮,许树青,等.靛玉红、色胺酮对 LPS 诱导 RAW264.7炎症细胞模型的抗炎作用研究[J].世界中西医结合杂志,2015,10(8):1069-1072.[29]臧思源.靛玉红抗脂多糖诱导人结肠上皮细胞炎症的作用及其机制研究[D].沈阳:辽宁中医药大学,2019.[30]Shao K,Wang T,Li T,et al.Indirubin regulates MPL and TNF expression in peripheral blood mononuclear cells from patients with primary immune thrombocytopenia[J].Experimental Hematology,2019,73:18-24.[31]李楠,柳越冬,王长洪,等.靛玉红缓解三硝基苯磺酸致大鼠溃疡性结肠炎及其机制研究[J].中国药理学通报,2018,34(12):1689-1692.[32]何新颖,唐志鹏,马贵同,等.靛玉红对DSS诱导结肠炎小鼠紧密连接蛋白ZO-1表达的影响[J].上海中医药杂志,2010,44(4):7-10,83.

相似文献/References:

[1]杜丽君.穴位埋线疗法联合口服美沙拉嗪治疗溃疡性结肠炎的 护理分析[J].医学信息,2018,31(05):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
　DU Li-jun.Nursing Analysis of Acupoint Catgut Embedding Therapy Combined with Oral Mesalazine in the Treatment of Ulcerative Colitis[J].Journal of Medical Information,2018,31(06):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
[2]张君红,李洪梅,井 洁,等.溃疡性结肠炎中西医结合治疗研究[J].医学信息,2018,31(09):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
　ZHANG Jun-hong,LI Hong-mei,JING Jie,et al.Study on the Treatment of Ulcerative Colitis with Integrated Traditional Chinese and Western Medicine[J].Journal of Medical Information,2018,31(06):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
[3]李 伟,徐 伟.溃疡性结肠炎中医干预治疗研究[J].医学信息,2022,35(09):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
　LI Wei,XU Wei.Study on Traditional Chinese Medicine Intervention Treatment of Ulcerative Colitis[J].Journal of Medical Information,2022,35(06):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
[4]汤胜男,赵党生,王凤仪,等.芍药汤治疗溃疡性结肠炎的研究[J].医学信息,2019,32(15):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
　TANG Sheng-nan,ZHAO Dang-sheng,WANG Feng-yi,et al.Study on Treating Ulcerative Colitis with Shaoyao Decoction[J].Journal of Medical Information,2019,32(06):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
[5]宋 崟,张 科.基于生物信息学方法探究溃疡性结肠炎的关键基因和通路[J].医学信息,2022,35(16):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
　SONG Yin,ZHANG Ke.Key Genes and Pathways of Ulcerative Colitis Based on Bioinformatics[J].Journal of Medical Information,2022,35(06):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
[6]华 琳,陈元旺,唐 静,等.溃疡性结肠炎患者外周血Tim-4 mRNA表达水平的变化及意义[J].医学信息,2019,32(21):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
　HUA Lin,CHEN Yuan-wang,TANG Jing,et al.Changes and Significance of Tim-4 mRNA Expression in Peripheral Blood of Patients with Ulcerative Colitis[J].Journal of Medical Information,2019,32(06):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
[7]徐 杰.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果比较[J].医学信息,2020,33(04):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
　XU Jie.Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis[J].Journal of Medical Information,2020,33(06):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
[8]牙韩清,郑琴芳,何志钧.溃疡性结肠炎相关结直肠癌手术治疗现况[J].医学信息,2020,33(07):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
　YA Han-qing,ZHENG Qin-fang,HE Zhi-jun.Surgical Treatment of Ulcerative Colitis-related Colorectal Cancer[J].Journal of Medical Information,2020,33(06):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
[9]王莹洁,戴迟兵.益生菌在炎症性肠病中的应用研究[J].医学信息,2020,33(22):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
　WANG Ying-jie,DAI Chi-bing.Study on the Application of Probiotics in Inflammatory Bowel Disease[J].Journal of Medical Information,2020,33(06):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
[10]朱 燕,刘大铭,刘全喜,等.溃疡性结肠炎中医诊疗思路[J].医学信息,2021,34(03):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]
　ZHU Yan,LIU Da-ming,LIU Quan-xi,et al.TCM Diagnosis and Treatment of Ulcerative Colitis[J].Journal of Medical Information,2021,34(06):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]

更新日期/Last Update: 1900-01-01